Postmarketing surveillance Is not used to promote products

Postmarketing surveillance of adverse reactions to drugs.

Three highly publicised outbreaks of iatrogenic disease have affected Britain in the past 20 years. The thalidomide affair resulted in legal controls on the investigation and marketing of new pharmaceutical products; the practolol episode produced a prolonged period of introspection but no further legislative action; and the problems with benoxaprofen should herald a re-evaluation of our curren...

Postmarketing surveillance of injury countermeasures.

Postmarketing surveillance for drug abuse.

Assessing actual abuse of prescribed medications requires postmarketing surveillance. In this article we discuss general systems of postmarketing surveillance that exist as of the end of 2002 in the United States and two medication-specific surveillance systems that were devised and tested. The two specific surveillance systems are compared with limitations highlighted. Postmarketing surveillan...

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies

Postmarketing drug surveillance is a crucial aspect of the clinical research activities in pharmacovigilance and pharmacoepidemiology. Successful utilization of available Electronic Health Record (EHR) data can complement and strengthen postmarketing safety studies. In terms of the secondary use of EHRs, access and analysis of patient data across different domains are a critical factor; we addr...

Active Postmarketing Drug Surveillance for Multiple Adverse Events

Active postmarketing drug surveillance is important for consumer safety. However, existing methods have limitations that prevent their direct use for active drug surveillance. One important consideration that has been absent thus far is the modeling of multiple adverse events and their interactions. In this paper, we propose a method to monitor the effect of a single drug on multiple adverse ev...